Press Release

LONDON, ONTARIO -- (MARKETWIRE) -- Jun 11, 2012 -- Stellar Pharmaceuticals Inc. ("Stellar" or "the Company") (OTCQB: SLXCF)(OTCBB: SLXCF)(PINKSHEETS: SLXCF), an emerging Canadian specialty pharmaceutical company focused on the acquisition, licensing, development and management of pharmaceutical and healthcare products with its primary focus on the Canadian market announced today that its President and Chief Executive Officer, Rob Harris, will present at 2:30 p.m. ET at the Bloom Burton & Co. Healthcare Investor Conference to be held on Thursday, June 21, 2012 at the Toronto Board of Trade, 1 First Canadian Place, Toronto, Ontario M5X 1C1.

About the Conference

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and European investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian public and private companies through presentations and break-out Q&A sessions.

Mr. Harris's presentation will be archived for 30 days on the Company's website at http://www.stellarpharma.com.

About Stellar Pharmaceuticals Inc.

Stellar and its subsidiary, Tribute Pharmaceuticals, is an emerging Canadian specialty pharmaceutical company focused on the acquisition, licensing, development and management of pharmaceutical and healthcare products with its primary focus on the Canadian market.

Stellar markets Bezalip® SR (bezafibrate), Soriatane® (acitretin), NeoVisc® (1.0% sodium hyaluronate solution) and Uracyst® (sodium chondroitin sulfate solution 2%) in the Canadian market. Additionally, NeoVisc® and Uracyst® are commercially available and are sold globally through various international partnerships. Stellar is currently in negotiations to license both NeoVisc® and Uracyst® in the United States and other international markets.

About Bloom Burton & Co.

Bloom Burton & Co. is Canada's largest and most active healthcare-specialized investment banking group. The team of healthcare specialists merges scientific, medical, clinical, intellectual property and commercial expertise with a strong understanding of the capital markets, to advise and raise capital for private and public companies. For more information, please visit www.bloomburton.com.

Forward-looking Statements

This press release contains certain forward-looking statements about Stellar as defined in the Private Securities Litigation Reform Act of 1995, which statements can be identified by the use of forward-looking terminology, such as "may", "will", "expect", "intend", "anticipate", "estimate", "predict", "plan" or "continue" or the negative thereof or other variations thereon or comparable terminology referring to future events or results. Forward-looking statements, by their nature, are subject to risks and uncertainties. Stellar's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including general economic conditions, the ability of Stellar to successfully integrate operations, and the timing of expenditures and expansion opportunities, any of which could cause actual results to vary materially from current results or anticipated future results. See Stellar's reports filed with the Canadian Securities Regulatory Authorities and the U.S. Securities and Exchange Commission from time to time for cautionary statements identifying important factors with respect to such forward-looking statements, including certain risks and uncertainties that could cause actual results to differ materially from results referred to in forward-looking statements. Stellar assumes no obligation to update the information contained in this press release to update forward-looking statements to reflect changed assumptions, the occurrence of anticipated events or changes in future operating results, financial condition or business over time.

For further information on Stellar, visit http://www.stellarpharma.com.

Contacts:
Stellar Pharmaceuticals Inc.
Scott Langille
CFO
519-434-1540
scott.langille@stellarpharma.com

Stellar Pharmaceuticals Inc.
Arnold Tenney
Chairman
705-445-9505
www.stellarpharma.com